Costs of treating infections caused by methicillin-resistant staphylococci and vancomycin-resistant enterococci

Area of Science:

• Infectious Diseases
• Clinical Pharmacology
• Hospital Epidemiology

Background:

• Healthcare-associated infections caused by multidrug-resistant organisms like methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecium (VREF) are associated with increased mortality, prolonged hospital stays, and high treatment costs.
• The widespread use of vancomycin for MRSA infections can inadvertently lead to the emergence of VREF colonization and infections, complicating patient care.
• Preventive strategies for MRSA and VREF include isolation, decontamination, stringent hygiene, ward closures, and screening of patients and healthcare personnel.

Purpose of the Study:

• To evaluate the efficacy of quinupristin/dalfopristin in treating infections caused by MRSA and VREF.
• To compare the clinical success rates of quinupristin/dalfopristin with vancomycin in treating nosocomial pneumonia.
• To assess the role of quinupristin/dalfopristin in managing costs associated with multidrug-resistant infections within a hospital setting.

Main Methods:

• Clinical efficacy of quinupristin/dalfopristin was assessed in patients with MRSA infections, including pneumonia, skin and soft tissue infections, and septicemia.
• Comparative analysis of clinical success rates between quinupristin/dalfopristin and vancomycin for nosocomial pneumonia.
• Evaluation of cost-effectiveness in the context of hospital infection control policies.

Main Results:

• Quinupristin/dalfopristin demonstrated effectiveness in treating various MRSA infections.
• Clinical success rates for quinupristin/dalfopristin were comparable to vancomycin in the treatment of nosocomial pneumonia.
• The implementation of quinupristin/dalfopristin, alongside hygiene and prudent antibiotic use, contributed to controlling costs associated with MRSA and VREF infections.

Conclusions:

• Quinupristin/dalfopristin is a viable therapeutic option for MRSA infections, including nosocomial pneumonia.
• This agent can be used effectively as an alternative to vancomycin, particularly when VREF emergence is a concern.
• Integrating quinupristin/dalfopristin into hospital antimicrobial stewardship programs can help mitigate the economic burden of multidrug-resistant bacterial infections.